For research use only. Not for therapeutic Use.
Mosnodenvir (JNJ-1802) is a pan-serotype dengue antiviral agent with a high barrier to resistance, and is safe and well-tolerated. Mosnodenvir blocks the NS3-NS4B interaction within the viral replication complex. Mosnodenvir shows picomolar to low nanomolar in vitro antiviral activity in mice[1][2].
| Catalog Number | I040915 |
| CAS Number | 2043343-94-6 |
| Synonyms | 2-(4-chloro-2-methoxyphenyl)-2-(3-methoxy-5-methylsulfonylanilino)-1-[5-(trifluoromethoxy)-1H-indol-3-yl]ethanone |
| Molecular Formula | C26H22ClF3N2O6S |
| Purity | ≥95% |
| InChI | InChI=1S/C26H22ClF3N2O6S/c1-36-17-9-15(10-18(11-17)39(3,34)35)32-24(19-6-4-14(27)8-23(19)37-2)25(33)21-13-31-22-7-5-16(12-20(21)22)38-26(28,29)30/h4-13,24,31-32H,1-3H3 |
| InChIKey | QNOPDDHSGQQLCV-UHFFFAOYSA-N |
| SMILES | COC1=CC(=CC(=C1)NC(C2=C(C=C(C=C2)Cl)OC)C(=O)C3=CNC4=C3C=C(C=C4)OC(F)(F)F)S(=O)(=O)C |
| Reference | [1]. Ackaert O, et al. Safety, tolerability and pharmacokinetics of JNJ-1802, a pan-serotype dengue direct antiviral small molecule, in a Phase 1, double-blind, randomized, dose-escalation study in healthy volunteers. Clin Infect Dis. 2023 May 10:ciad284. [2]. Goethals O, et al. Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates. Nature. 2023 Mar;615(7953):678-686. |
